Fillano JJ, Goldenthal MJ, Rhodes CH, Marn-Garca J
It has FDA Breakthrough Therapy designation specifically for MASH
Mi trtnik, ha abbahagyom a GLP-1 gygyszereket
While nausea, vomiting, and diarrhea are the most commonly reported gastrointestinal adverse effects with GLP-1-based therapies (occurring in 15-40% of patients depending on the agent and dose), FDA prescribing information for several of these medications does list dyspepsia (indigestion) and, in some cases, gastroesophageal reflux disease (GERD) as reported adverse reactions
However, fortified plant-derived foods are available (i.e., certain types of bread and cereals, some vegetables), as well as milk infant formulas [31]
======================================== Who Is at Higher Risk